|
|
| General |
| Study Status |
Ongoing |
Application Number /
Requirement Number |
P150033 / PAS002 |
| Date Original Protocol Accepted |
03/08/2016
|
| Date Current Protocol Accepted |
04/22/2026
|
| Study Name |
Micra Transcatheter Pacing System PAS
|
| Device Name |
MEDTRONIC MICRA TRANSCATHETER PACEMAKER SYSTEM
|
| Clinical Trial Number(s) |
NCT02004873
|
| General Study Protocol Parameters |
| Study Design |
Prospective Cohort Study
|
| Data Source |
Sponsor Registry
|
| Comparison Group |
No Control
|
| Analysis Type |
Descriptive
|
| Detailed Study Protocol Parameters |
| Study Objectives |
Micra PAS is a global, prospective, observational, multicenter study.
|
| Study Population |
Patients intended to be implanted with a Micra system are eligible for enrollment into the Micra PAS.
Micra IDE (G130245) Study and the Micra Continued Access Study (G130245) patients who remain active at the time of
product approval are eligible for continued follow-up in the PAS.
|
| Sample Size |
The primary objective #1 requires a minimum of 1741 patients undergoing Micra system implant attempts.
Primary objective #2 requires a minimum sample size of 200 at 9 years. It is anticipated that approximately 150 Micro End of Device Service events will be captured. To account for attrition due to consented patient
withdrawing prior to an implant procedure, the projected enrollment number required for this study is 1830 patients.
* In order to ensure the effective sample size at the end of the study this protocol states that the study attrition will be assessed annually.
The annual attrition rate will be compared to the projected size indicated in Table 6 of the protocol (link below). If significant higher
attrition (more than 5% increase) is observed, supplemental enrollments will be considered.
|
| Key Study Endpoints |
Primary Objective #1 (Acute - 30 days):
To estimate acute complication rate related to the Micra system and/or implant procedure. Individual 30-day
complication rates will be reported for but not limited to:
cardiac perforation, pericardial effusion, dislodgement, embolization, serious groin complications and infections.
- 1741 Micra system implant procedure ensure complication detection and produces a 2-sided 95%
CI width of 1.0% when the event rate is 1% Primary Objective #2 (Chronic 9 years):
To estimate the 9-year complication free survival rate of the Micra system.
- 500 patients at 9-years produces a 2-sided CI width of 6.5% with a CI lower limit of 85.0% was conservatively assumed during the initial design stage of the study in the calendar year 2105
Secondary Objective (Micra TPS EDS):
To characterize treatment and/or procedure related to Micra TPS End of Device Service. Any one of the following
revision scenario contributes equally to the approximately 150 EDS events. Possible revisions scenarios include:
- Explant of Micra System with new leadless pacemaker system
- Explant of Micra System with new transvenous pacemaker system
- Implant of new leadless pacemaker without explant of Micra System (e.g., set to OOO or programmed to a back-up pacing mode)
- Implant of new transvenous pacemaker system without explant of Micra System (e.g., set to OOO or programmed to a back-up pacing mode)
|
| Follow-up Visits and Length of Follow-up |
The study will complete when a minimum of 200 patients have completed 9 years of follow-up. The total estimated PAS duration is 11 years.
|
